KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 122 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 4.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $9,409 | +12.5% | 6,231 | -0.2% | 0.00% | – |
Q3 2023 | $8,364 | -25.1% | 6,242 | 0.0% | 0.00% | -100.0% |
Q2 2023 | $11,173 | -32.7% | 6,242 | +46.2% | 0.00% | 0.0% |
Q1 2023 | $16,610 | +5.7% | 4,270 | -7.6% | 0.00% | 0.0% |
Q4 2022 | $15,715 | -37.7% | 4,622 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $25,236 | +110.5% | 4,622 | +73.9% | 0.00% | 0.0% |
Q2 2022 | $11,988 | -66.2% | 2,658 | -44.8% | 0.00% | 0.0% |
Q1 2022 | $35,464 | -57.5% | 4,812 | -62.9% | 0.00% | 0.0% |
Q4 2021 | $83,461 | +24.3% | 12,980 | +12.5% | 0.00% | 0.0% |
Q3 2021 | $67,134 | -70.8% | 11,535 | -48.2% | 0.00% | -66.7% |
Q2 2021 | $229,589 | +12.7% | 22,247 | +14.9% | 0.00% | 0.0% |
Q1 2021 | $203,730 | -39.5% | 19,366 | -10.9% | 0.00% | -40.0% |
Q4 2020 | $336,535 | +6.0% | 21,740 | 0.0% | 0.01% | -16.7% |
Q3 2020 | $317,404 | -22.9% | 21,740 | 0.0% | 0.01% | -14.3% |
Q2 2020 | $411,756 | +17.4% | 21,740 | +19.1% | 0.01% | 0.0% |
Q1 2020 | $350,775 | -10.9% | 18,260 | -11.1% | 0.01% | 0.0% |
Q4 2019 | $393,848 | +92.0% | 20,545 | -3.6% | 0.01% | +133.3% |
Q3 2019 | $205,079 | +636.4% | 21,318 | +358.6% | 0.00% | – |
Q2 2019 | $27,847 | -81.7% | 4,649 | -71.4% | 0.00% | -100.0% |
Q4 2018 | $152,497 | -45.0% | 16,275 | 0.0% | 0.00% | -40.0% |
Q3 2018 | $277,163 | -99.9% | 16,275 | 0.0% | 0.01% | +25.0% |
Q2 2018 | $276,512,000 | +75.8% | 16,275 | +38.9% | 0.00% | +100.0% |
Q1 2018 | $157,269,000 | +146880.4% | 11,719 | +4.8% | 0.00% | +100.0% |
Q4 2017 | $107,000 | -55.6% | 11,177 | -49.0% | 0.00% | -50.0% |
Q3 2017 | $241,000 | +21.7% | 21,911 | 0.0% | 0.00% | +100.0% |
Q2 2017 | $198,000 | -29.5% | 21,911 | 0.0% | 0.00% | -50.0% |
Q1 2017 | $281,000 | +36.4% | 21,911 | 0.0% | 0.00% | +100.0% |
Q4 2016 | $206,000 | +9.0% | 21,911 | +12.6% | 0.00% | 0.0% |
Q3 2016 | $189,000 | +39.0% | 19,451 | -3.8% | 0.00% | 0.0% |
Q2 2016 | $136,000 | -39.3% | 20,210 | +19.4% | 0.00% | -50.0% |
Q4 2015 | $224,000 | +25.8% | 16,920 | 0.0% | 0.00% | +100.0% |
Q3 2015 | $178,000 | -61.3% | 16,920 | 0.0% | 0.00% | -66.7% |
Q2 2015 | $460,000 | +25.3% | 16,920 | +72.8% | 0.00% | 0.0% |
Q4 2014 | $367,000 | +7.3% | 9,793 | 0.0% | 0.00% | +50.0% |
Q3 2014 | $342,000 | -25.0% | 9,793 | 0.0% | 0.00% | -33.3% |
Q2 2014 | $456,000 | +132.7% | 9,793 | +54.3% | 0.00% | +200.0% |
Q1 2014 | $196,000 | -16.2% | 6,346 | -37.9% | 0.00% | -50.0% |
Q4 2013 | $234,000 | – | 10,221 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 4,827,078 | $82,205,000 | 4.43% |
Palo Alto Investors LP | 4,663,324 | $79,416,000 | 3.21% |
Private Capital Advisors, Inc. | 473,901 | $8,071,000 | 2.23% |
DOHENY ASSET MANAGEMENT /CA | 215,445 | $3,669,000 | 1.92% |
Sandia Holdings, LLC | 119,739 | $2,039,000 | 0.96% |
Capital Impact Advisors, LLC | 102,006 | $1,744,000 | 0.60% |
Birchview Capital, LP | 50,000 | $852,000 | 0.55% |
EMERALD ADVISERS, LLC | 694,068 | $11,820,000 | 0.43% |
EMERALD MUTUAL FUND ADVISERS TRUST | 647,307 | $11,024,000 | 0.37% |
Schonfeld Strategic Advisors LLC | 418,100 | $7,121,000 | 0.32% |